Insilico Medicine Mediaroom - PR Newswire APAC

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

Single 2.6B-parameter model achieves state-of-the-art performance across drug discovery benchmarks ...

2026-03-03 22:25 2955

Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery

AI-Powered R&D Acceleration: Insilico Medicine and CMS announce multiple collaborations in central nervous system and autoimmune diseases

CAMBRIDGE, Mass., Feb. 10, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 03696.HK), a clinica...

2026-02-10 21:00 5687

Insilico Medicine Appoints Halle Zhang, PhD (Med), as Vice President, Clinical Development - Oncology

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinic...

2026-02-06 21:00 7558

Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications

* NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cyto...

2026-02-05 21:00 6241

Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501

Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilic...

2026-02-03 22:00 6561

Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies

CAMBRIDGE, Mass., Jan. 27, 2026 /PRNewswire/ -- Insilico Medicine, a clinical-stage biotechnology c...

2026-01-27 22:00 7422

Insilico Medicine Receives IND Approval from FDA for ISM8969, an AI-empowered Potential Best-in-class NLRP3 Inhibitor

* Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves ...

2026-01-23 21:30 13408

Insilico Medicine Launches Science MMAI Gym to Transform Frontier LLMs into Pharmaceutical-Grade Scientific Engines

* New "AI GYM for Science" dramatically boosts the biological and chemical intelligence of any ca...

2026-01-22 22:37 8053

Insilico Medicine and Hygtia Therapeutics Enter New Global Strategic Collaboration to Co-Develop Novel Brain Penetrant NLRP3 Inhibitor for CNS Diseases treatment

* Insilico Medicine and Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Fund of Fosun Health...

2026-01-21 08:15 6333

Insilico Medicine Completes First Patient First Dose in BETHESDA: A Phase II Trial for Garutadustat (ISM5411), the Gut-restricted AI-driven PHD Inhibitor for the Treatment of Inflammatory Bowel Disease

CAMBRIDGE, Mass., Jan. 12, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage, g...

2026-01-12 21:30 1530

Insilico Medicine Announce US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology

* Insilico Medicine achieved an R&D collaboration with Servier valued at up to US$888 million, fo...

2026-01-05 08:30 3511

Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO

HONG KONG, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discove...

2025-12-30 17:00 12470

Insilico Medicine Lists on Hong Kong Stock Exchange, Showing AI Drug Discovery Momentum with 2025's Largest Hong Kong Biotech IPO

Insilico Medicine and TaiGen Achieves License Agreement to Develop and Commercialize AI-driven PHD Inhibitor for Anemia of Chronic Kidney Disease (CKD)

* Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area ...

2025-12-12 20:00 3516

Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1

* AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, success...

2025-12-02 22:00 2506

Insilico Medicine Launches Nach01 Foundation Model on AWS Marketplace to Help Accelerate Generative Chemistry Innovation

CAMBRIDGE, Mass., June 10, 2025 /PRNewswire/ -- Insilico Medicine , a clini...

2025-06-10 21:00 2527

Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach

* Phase IIa study results of Rentosertib were published simultaneously in NatureMedicine(IF = 58....

2025-06-03 22:27 3269

Insilico Medicine Announces Nature Medicine Publication of Phase IIa Results Evaluating Rentosertib, the Novel TNIK Inhibitor for Idiopathic Pulmonary Fibrosis (IPF) Discovered and Designed with a Pioneering AI Approach

Insilico Medicine Secures $110 Million Series E Financing to Advance AI-Driven Drug Discovery Innovation

CAMBRIDGE, Mass., March 13, 2025 /PRNewswire/ -- Insilico Medicine("Insilico"), a clinical-stage ge...

2025-03-13 21:00 3531

Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology

* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discove...

2025-01-10 22:00 2828

Insilico Received Positive Topline Results from Two Phase 1 Trials of ISM5411, New Drug Designed Using Generative AI for the Treatment of Inflammatory Bowel Disease

* Two separate Phase I studies conducted in Australia and in China indicate that ISM5411 was gene...

2025-01-07 22:00 2168

Nature Biotechnology | Generative Chemistry Enables Insilico to Develop Gut-Restricted PHD Inhibitors Promising for Intestinal Mucosal Barrier Repair and Immunomodulation

* The study presents the journey of designing and optimizing novel gut-restricted PHD inhibitors ...

2024-12-11 22:25 2555

Latest News